Cardiovascular disease in hemodialysis patients Circulatory System
Conditions
Interventions
This was a prospective study involving a cohort of stable patients recruited from eligible patients who were undergoing hemodialysis at the study centre hemodialysis clinic three times a week during t
and carvedilol on days 8 through 14. The carvedilol was given in increasing doses, from a minimum of 3.123 mg (twice a day) on day 8 to a maximum of 9.375 mg (twice a day) on day 14. Noninvasive (Holt
Sponsors
University of Sao Paulo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 18 years or older 2. Having chronic kidney disease (CKD) 3. Having been on regular hemodialysis for more than 6 months 4. Having a hemoglobin level >10 mg/dl 5. Having a Kt/V >1.2 in more than three consecutive measures 6. Patients gave written informed consent
Exclusion criteria
Exclusion criteria: 1. Active liver disease 2. Any other decompensated disease 3. Previously used beta-blockers 4. Active infection 5. Hospitalized
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean plasma norepinephrine level measured by High Performance Liquid Chromatography (HPLC) at 0 and 14 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of ventricular arrhythmias registered by Holter monitoring at 0 and 14 days | — |
Countries
Brazil
Outcome results
None listed